Contrast-Induced Nephropathy and the Vascular Patient

Ishibashi Y. , Yamauchi M. , Musha H. , et al. Impact of contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal insufficiency patients undergoing coronary catheterization. Angiology. IN PRESS.

Shaker O. , El-Shehaby A. , El-Khatib M. Early diagnostic markers for contrast nephropathy in patients undergoing coronary angiography. Angiology. IN PRESS.

Gleeson TG , Bulugahapitiya S. Contrast-induced nephropathy. AJR Am J Roentgenol. 2004;183(6):1673-1689.

Goldenberg I. , Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172(11):1461-1471.

Tepel M. , Aspelin P. , Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006;113(14): 1799-1806.

Brady HR , Singer GG Acute renal failure. Lancet. 1995; 346(8989):1533-1540.

Tepel M. , van der Giet M. , Schwarzfeld C. , Lauder U. , Liermann D. , Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343(3):180-184.

Paraskevas KI , Bessias N. , Perdikides TP , Mikhailidis DP Statins and venous thromboembolism: a novel effect of statins? Curr Med Res Opin. 2009 ;25(7):1807-1809.

Paraskevas KI , Stathopoulos V. , Mikhailidis DP Pleiotropic effects of statins: implications for a wide range of diseases. Curr Vasc Pharmacol. 2008;6(4):237-239.

Zhou Q. , Liao JK Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J. 2010;74(5):818-826.

Sadowitz B. , Maier KG , Gahtan V. Basic science review: statin therapy-Part I: the pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg. 2010;44(4):241-251.

Beri A. , Contractor T. , Khasnis A. , Thakur R. Statins and the reduction of sudden cardiac death: antiarrhythmic or anti-ischemic effect? Am J Cardiovasc Drugs. 2010;10(3):155-164.

Athyros VG , Tziomalos K. , Karagiannis A. , Mikhailidis DP Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention Curr Vasc Pharmacol. 2009;7(3):264-266.

Attallah N. , Yassine L. , Musial J. , Yee J. , Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol. 2004; 62(4):273-278.

Khanal S. , Attallah N. , Smith DE , et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118(8):843-849.

Zhao JL , Yang YJ , Zhang YH , You SJ , Wu YJ , Gao RL Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. Int J Cardiol . 2008;126(3):435-436.

Patti G. , Nusca A. , Chello M. , et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2008;101(3):279-285.

Yoshida S. , Kamihata H. , Nakamura S. , et al. Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency . J Cardiol. 2009;54(2):192-198.

Kandula P. , Shah R. , Singh N. , Markwell SJ , Bhensdadia N. , Navaneethan SD Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention. Nephrology (Carlton). 2010;15(2):165-170.

Xinwei J. , Xianghua F. , Jing Z. , et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2009; 104(4):519-524.

Alnaeb ME , Youssef F. , Mikhailidis DP , Hamilton G. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease . Angiology. 2006;57(1):65-71.

Writing Group Members. Lloyd-Jones D. , Adams RJ , Carnethon M. , et al;. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2010 update: a report from the America Heart Association. Circulation. 2010;121(7):e46-e215.

Proceedings of a Centers for Disease Control and Prevention Expert Panel Workshop: developing a comprehensive public health strategy for preventing the development, progression, and complications of chronic kidney disease. March 2007. Am J Kidney Dis. 2009 ;53(3 suppl 3):S1-S125.

Collins AJ , Foley RN , Herzog C. , et al. Excerpts from the US Renal Data System 2009 Annual Data Report . Am J Kidney Dis. 2010;55(1 suppl 1):S1-S420, A6-A7.

Preis SR , Hwang SJ , Coady S. , et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009;119(13):1728-1735.

Athyros VG , Mitsiou EK , Tziomalos K. , Karagiannis A. , Mikhailidis DP Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opin Pharmacother. 2010;11(5):723-730.

Athyros VG , Mikhailidis DP , Papageorgiou AA , et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57(7):728-734.

Collins R. , Armitage J. , Parish S. , Sleight P. , Peto R. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363(9411):757-767.

LaRosa JC , Grundy SM , Waters DD , et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-1435.

Spargias K. , Adreanides E. , Demerouti E. , et al. Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2009;120(18):1793-1799.

Hernández F. , Mora L. , García-Tejada J. , et al. Comparison of iodixanol and ioversol for the prevention of contrast-induced nephropathy in diabetic patients after coronary angiography or angioplasty. Rev Esp Cardiol. 2009;62(12):1373-1380.